MHRP is a leading brand at the forefront of the fight against HIV, dedicated to protecting U. S. With a strong focus on HIV vaccine research and development, MHRP has gained international recognition through groundbreaking studies like the RV144 Thai trial, the first-ever HIV vaccine study to show modest efficacy in preventing HIV in humans.

This success has allowed MHRP to establish collaborations with top research institutions worldwide. Supported by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), MHRP conducts research at sites across Africa and Asia, employing a combination of rigorous science, strategic partnerships, and careful site development.

MHRP also collaborates closely with the U. S. National Institute of Allergy and Infectious Diseases (NIAID).

Beyond vaccine research, MHRP has expanded into HIV threat assessment, diagnostics, epidemiology, and acute infection and functional cure research. The brand is also exploring injectable countermeasures to prevent HIV transmission during high-risk blood transfusions. MHRP's mission is further reinforced by its integration of prevention and treatment programs in local communities, made possible through support from the U.

S. President's Emergency Plan for AIDS Relief (PEPFAR). As part of the U.

S. Army Medical Research and Development Command (USAMRDC) under the Army Futures Command (AFC), MHRP is committed to developing and advancing effective solutions such as vaccines, monoclonal antibodies, therapeutics, and diagnostics to combat HIV and related infections. To learn more about MHRP's strategic plan, please visit the website